Intrinsic Value
Keros Therapeutics, Inc. · KROS
Conservative
More adverse but historically defensible assumptions.
-$20,907,212,349,334.70
Base
The model's central intrinsic-value estimate.
-$29,853,190,503,828.30
Optimistic
More favorable but historically defensible assumptions.
-$37,720,859,361,989.10
Scenarios are the same model run under different but historically defensible assumptions. They are not price targets. Where a valuation gap is shown it is a comparison with a recent close, not a forecast return; where the price is stale, no gap is shown at all.
Model confidence: 61%Valuation as of Sep 21, 2026Latest filing used Mar 4, 2026
Confidence reflects data completeness, accounting quality, and model reliability. It is not a probability of future price.
Valuation drivers
- Normalized operating margin
- -3109.7%
- Normalized NOPAT margin
- -2628.2%
- Revenue growth
- 2251.0%
- WACC
- 9.20%
- Terminal growth
- 2.50%
- Reinvestment method
- direct reinvestment
- Terminal-value share
- 87.0%
Model notes (5)
- Terminal value is 87% of enterprise value (Base case)
- Terminal value is 84% of enterprise value (Conservative case)
- Terminal value is 89% of enterprise value (Optimistic case)
- Interest-bearing debt unavailable
- Minority interest not reported
Model details
- Normalization
- V1
- Scenario
- V2
- Confidence
- V1
- Engine version
- valuation-1.0.1-share-units-terminal
- Data snapshot
- filed:2026-03-04